Osteomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Osteomyelitis Pipeline Drugs Market Overview
Osteomyelitis is an infection in a bone. Infections can reach a bone by traveling through the bloodstream or spreading from nearby tissue. Symptoms include fever, pain in the infection, swelling, warmth, redness over the area of the infection, and irritability. Risk factors are bone fracture, sickle cell disease, chemotherapy, diabetes, and peripheral arterial disease. Treatment includes surgery and oral antibiotics.
The Osteomyelitis pipeline drugs market research report provide comprehensive information on the therapeutics under development for Osteomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteomyelitis and features dormant and discontinued projects.
Key Targets in the Osteomyelitis Pipeline Drugs Market
The key targets in the Osteomyelitis pipeline drugs market are Bacterial Cell Wall, 16S Ribosomal RNA, 23S Ribosomal RNA, DNA Gyrase, DNA Topoisomerase IV, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, Penicillin Binding Protein, and Staphylococcus aureus Bifunctional Autolysin.
Osteomyelitis Pipeline Drugs Analysis Market by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Osteomyelitis Pipeline Products Market
The key mechanisms of action in the Osteomyelitis pipeline products market are Bacterial Cell Wall Disruptor, 16S Ribosomal RNA Inhibitor, 23S Ribosomal RNA Inhibitor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, Penicillin Binding Protein Inhibitor, and Staphylococcus aureus Bifunctional Autolysin Inhibitor.
Osteomyelitis Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
Key Routes of Administration in the Osteomyelitis Pipeline Products Market
The key routes of administration in the Osteomyelitis pipeline products market are intravenous, oral, and parenteral.
Osteomyelitis Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Osteomyelitis Pipeline Drugs Market
The key molecule types in the Osteomyelitis pipeline drugs market are small molecule, biologic, monoclonal antibody, and recombinant enzyme.
Osteomyelitis Pipeline Drugs Market Analysis by Molecule Type
For more molecule type insights, download a free report sample
Major Companies in the Osteomyelitis Pipeline Products Market
Some of the major companies in the Osteomyelitis pipeline products market are Adaptive Phage Therapeutics Inc, BioVinc LLC, ContraFect Corp, Debiopharm International SA, Integrated BioTherapeutics Inc, Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, Nabriva Therapeutics Plc, and Sonoran Biosciences Inc.
Osteomyelitis Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Overview
Key targets | Bacterial Cell Wall, 16S Ribosomal RNA, 23S Ribosomal RNA, DNA Gyrase, DNA Topoisomerase IV, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, Penicillin Binding Protein, and Staphylococcus aureus Bifunctional Autolysin |
Key mechanism of action | Bacterial Cell Wall Disruptor, 16S Ribosomal RNA Inhibitor, 23S Ribosomal RNA Inhibitor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, Penicillin Binding Protein Inhibitor, and Staphylococcus aureus Bifunctional Autolysin Inhibitor |
Key routes of administration | Intravenous, Oral, and Parenteral |
Key molecule type | Small Molecule, Biologic, Monoclonal Antibody, and Recombinant Enzyme |
Major companies | Adaptive Phage Therapeutics Inc, BioVinc LLC, ContraFect Corp, Debiopharm International SA, Integrated BioTherapeutics Inc, Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, Nabriva Therapeutics Plc, and Sonoran Biosciences Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteomyelitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Osteomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Osteomyelitis (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteomyelitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
BioVinc LLC
ContraFect Corp
Debiopharm International SA
Integrated BioTherapeutics Inc
Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
Nabriva Therapeutics Plc
Sonoran Biosciences Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Osteomyelitis pipeline products market?
The key targets in the Osteomyelitis pipeline products market are Bacterial Cell Wall, 16S Ribosomal RNA, 23S Ribosomal RNA, DNA Gyrase, DNA Topoisomerase IV, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, Penicillin Binding Protein, and Staphylococcus aureus Bifunctional Autolysin.
-
What are the key mechanisms of action in the Osteomyelitis pipeline products market?
The key mechanisms of action in the Osteomyelitis pipeline products market are Bacterial Cell Wall Disruptor, 16S Ribosomal RNA Inhibitor, 23S Ribosomal RNA Inhibitor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, Penicillin Binding Protein Inhibitor, and Staphylococcus aureus Bifunctional Autolysin Inhibitor.
-
What are the key routes of administration in the Osteomyelitis pipeline products market?
The key routes of administration in the Osteomyelitis pipeline products market are intravenous, oral, and parenteral.
-
What are the key molecule types in the Osteomyelitis pipeline products market?
The key molecule types in the Osteomyelitis pipeline products market are small molecule, biologic, monoclonal antibody, and recombinant enzyme.
-
Which are the major companies in the Osteomyelitis pipeline products market?
Some of the major companies in the Osteomyelitis pipeline products market are Adaptive Phage Therapeutics Inc, BioVinc LLC, ContraFect Corp, Debiopharm International SA, Integrated BioTherapeutics Inc, Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, Nabriva Therapeutics Plc, and Sonoran Biosciences Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.